Sellas Life Sciences Group, Inc.

Sellas Life Sciences Group, Inc. company information, Employees & Contact Information

We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.

Company Details

Employees
20
Founded
-
Address
7 Times Square,
Phone
212-710-9686
Email
in****@****ife.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, NY
Looking for a particular Sellas Life Sciences Group, Inc. employee's phone or email?

Sellas Life Sciences Group, Inc. Questions

News

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 - Yahoo Finance

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 Yahoo Finance

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum - Sahm

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum Sahm

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update - GlobeNewswire

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update GlobeNewswire

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally - ts2.tech

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally ts2.tech

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside - ts2.tech

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside ts2.tech

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts - Yahoo Finance

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts Yahoo Finance

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - GlobeNewswire

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification GlobeNewswire

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech? - ts2.tech

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech? ts2.tech

Major AML Treatment Updates: SELLAS Life Sciences to Reveal Phase 3 REGAL Results & New Drug Progress - Stock Titan

Major AML Treatment Updates: SELLAS Life Sciences to Reveal Phase 3 REGAL Results & New Drug Progress Stock Titan

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - Yahoo Finance

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML Yahoo Finance

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Nasdaq

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - Yahoo Finance

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase Yahoo Finance

SELLAS (NASDAQ: SLS) to conduct 1x1 investor meetings at J.P. Morgan Forum Nov 12 - Stock Titan

SELLAS (NASDAQ: SLS) to conduct 1x1 investor meetings at J.P. Morgan Forum Nov 12 Stock Titan

SELLAS Life Sciences Group Announces Exercise of Existing - GlobeNewswire

SELLAS Life Sciences Group Announces Exercise of Existing GlobeNewswire

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Yahoo Finance

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update Yahoo Finance

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes - Yahoo Finance

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes Yahoo Finance

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update Yahoo Finance

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - Yahoo Finance

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia Yahoo Finance

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - Yahoo Finance

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia Yahoo Finance

SELLAS Life Sciences Achieves Major Milestone: Added to Russell Indexes Ahead of Key Cancer Trial Results - Stock Titan

SELLAS Life Sciences Achieves Major Milestone: Added to Russell Indexes Ahead of Key Cancer Trial Results Stock Titan

SELLAS Phase 3 Cancer Drug GPS Clears Critical Safety Review, Final Data Expected This Year - Stock Titan

SELLAS Phase 3 Cancer Drug GPS Clears Critical Safety Review, Final Data Expected This Year Stock Titan

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - citybiz

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board citybiz

Major Healthcare Investor Backs SELLAS with $25M Deal - Here's the Full Structure - Stock Titan

Major Healthcare Investor Backs SELLAS with $25M Deal - Here's the Full Structure Stock Titan

SELLAS Life Sciences Proposed Public Offering - citybiz

SELLAS Life Sciences Proposed Public Offering citybiz

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering - citybiz

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering citybiz

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market - Stock Titan

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market Stock Titan

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout (NASDAQ:SLS) - Seeking Alpha

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout (NASDAQ:SLS) Seeking Alpha

SELLAS Life Sciences Appoints Andrew Elnatan as Vice President - citybiz

SELLAS Life Sciences Appoints Andrew Elnatan as Vice President citybiz

Top Sellas Life Sciences Group, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant